- Home
- IMRX
as 12-18-2024 10:38am EST
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 73.2M | IPO Year: | 2021 |
| Target Price: | $12.80 | AVG Volume (30 days): | 801.9K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.00 - $8.07 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Immuneering Corporation News
IMRX Breaking Stock News: Dive into IMRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Benzinga
5 days ago
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
MT Newswires
5 days ago
Morgan Stanley Downgrades Immuneering to Underweight From Equalweight, Removes $4 Price Target, Sets Base Case Range of $1-$5
GlobeNewswire
6 days ago
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
GlobeNewswire
21 days ago
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
Simply Wall St.
a month ago
Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor
GlobeNewswire
a month ago
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Zacks
2 months ago
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
Compare IMRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMRX Immuneering Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.